EffRx Signs Expansion of Licensing Deal with Nycomed for Its Novel Effervescent Osteoporosis Drug EX101

JUPITER, FLORIDA, March 30, 2009. The Florida based drug delivery company EffRx, Inc. and the pharmaceutical company Nycomed today announced that they have signed an expansion of territories in their licensing deal for EffRx’s proprietary drug EX101 (effervescent alendronate), for the treatment of osteoporosis. A previous licensing agreement covering Europe, Russia, the Middle East, North Africa, Latin America and Canada was signed in January 2009.Under the terms of the agreement, EffRx will receive from Nycomed additional upfront and milestone payments of up to US$15m. This brings the